|Mr. Peter H. Nielsen MBA||Co-Founder, Chairman, CEO, Pres, CFO and Treasurer||596.46k||N/A||68|
|Dr. Ulrich W. Mueller Ph.D.||Chief Operating Officer and Sec.||406.3k||N/A||50|
|Dr. Ana Tari Ashizawa Ph.D., MBA||Director of Research||N/A||N/A||N/A|
|Dr. Suzanne Kennedy Ph.D.||Director of Corp. Devel.||N/A||N/A||N/A|
|Ms. Tara Sadeghi M.P.H||Director of Clinical Operations||N/A||N/A||56|
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Bio-Path Holdings, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 2; Compensation: 9.